EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin

Yoshiyuki Miyazawa iD, Takanori Shimizu, Yoshitaka Sekine, Seiji Arai iD, Akira Ohtsu, Yuji Fujizuka, Masashi Nomura, Hidekazu Koike, Hiroshi Matsui, Kazuhiro Suzuki iD

IJU Case Reports · 2023-01 · 6 (1) · 37-40

DOI: 10.1002/iju5.12543 ↗

Kurz gefasst

Fallbericht in der Zeitschrift IJU Case Reports, online erschienen am 09.10.2022. Verfasst von Yoshiyuki Miyazawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Gunma University Graduate School of Medicine Gunma Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Several prostate cancers carry homologous recombination repair mutations that respond to olaparib. Because of the mechanism, the efficacy of platinum‐based therapy can be used to predict the efficacy of poly(adenosine diphosphate‐ribose) polymerase inhibitors such as olaparib. Case presentation We experienced two neuroendocrine prostate cancer patients who achieved a response duration of more than 1 year with platinum‐based therapy. Case 1 had a BRCA2 mutation in the germline and case 2 had a BRCA2 mutation in a somatic chromosome only. Both patients responded well to olaparib.

Conclusion

Cisplatin and olaparib may overlap in response due to their medicinal action. It may be useful to consider genetic testing in some CRPC patients who have responded to cisplatin.

Schlagwörter

Stichwörter der Autor:innen

BRCAcastration‐resistant prostate cancerneuroendocrine prostate cancerpoly(adenosine diphosphate‐ribose) polymeraseprostate cancer

Autor:innen und Institutionen

  • Department of Urology Gunma University Graduate School of Medicine Gunma Japan.

ORCID-Profile: Yoshiyuki Miyazawa, Seiji Arai, Kazuhiro Suzuki

Zitieren

APA

Miyazawa, Y., Shimizu, T., Sekine, Y., Arai, S., Ohtsu, A., Fujizuka, Y., Nomura, M., Koike, H., Matsui, H., & Suzuki, K. (2023). Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin. IJU Case Reports, 6(1), 37-40. https://doi.org/10.1002/iju5.12543

Vancouver

Miyazawa Y, Shimizu T, Sekine Y, Arai S, Ohtsu A, Fujizuka Y, et al. Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin. IJU Case Reports. 2023;6(1):37-40. doi:10.1002/iju5.12543

BibTeX
@article{Miyazawa2023,
  author = {Miyazawa, Yoshiyuki and Shimizu, Takanori and Sekine, Yoshitaka and Arai, Seiji and Ohtsu, Akira and Fujizuka, Yuji and Nomura, Masashi and Koike, Hidekazu and Matsui, Hiroshi and Suzuki, Kazuhiro},
  title = {Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin},
  journal = {IJU Case Reports},
  year = {2023},
  volume = {6},
  number = {1},
  pages = {37--40},
  doi = {10.1002/iju5.12543}
}
Kostenlos starten →